SLNO — Soleno Therapeutics, Inc.

Summary of Soleno Therapeutics Q4 and Full Year 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $91.7 million, a nearly 40% increase from Q3 2025 ($66 million).
• Full Year 2025 Revenue: $190.4 million, achieved in less than 9 months of sales following the launch of VYKAT XR.
• Net Income: $20.9 million for the full year, compared to a net loss of $175.9 million in 2024.
• Cash Flow: Generated $48.7 million from operating activities in Q4, ending the year with over $506 million in cash, cash equivalents, and marketable securities.
• Discontinuation Rates: Approximately 12% related to adverse events, with a total discontinuation rate around 15%. Long-term expectations are between 15% to 20%.

2. Strategic Updates and Business Highlights

• VYKAT XR Launch: Successfully launched as the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome (PWS). By year-end, 1,250 patient start forms were submitted, with 859 patients actively treated.
• Commercialization Strategy: Focus on expanding prescriber base and increasing engagement with caregivers and healthcare providers. 630 unique prescribers were recorded by year-end.
• EU Market Entry: Submitted marketing authorization application for DCCR in the EU, with responses to Day 120 questions submitted. Anticipated decision by mid-2026.
• New Indications: Plans to explore VYKAT XR for glycogen storage disease type 1 (GSD 1), with an IND filing expected in H1 2026.

3. Forward Guidance and Outlook

• Patient Start Forms: Guidance of capturing an additional 1,000 patient start forms over the next 9 to 12 months.
• Market Penetration: Potential for higher market penetration in PWS due to lack of existing treatments, with expectations for 40-50% penetration in the coming years.
• Commercial Expansion: Continued focus on deepening experience and adoption in leading academic centers and expanding into community settings.

4. Bad News, Challenges, or Points of Concern

• Discontinuation Rates: While current rates are acceptable, any increase could impact active patient growth.
• Seasonality Effects: Anticipated impacts on Q1 revenue due to co-pay resets and potential shifts in patient visits.
• Regulatory Risks: Uncertainty surrounding the EU approval process, particularly regarding the adequacy of clinical data for efficacy.

5. Notable Q&A Insights

• Patient Start Forms: The cadence of patient start forms is expected to be steady over the year rather than spiking in any particular quarter.
• Market Dynamics: The company is observing a mix of factors affecting patient growth, including insurance-related delays and the time required for benefits assessments.
• Efficacy and Patient Retention: Anecdotal evidence suggests that patients who remain on VYKAT XR experience benefits, primarily in managing hyperphagia, which may reduce discontinuation rates.
• Future Indications: Interest in exploring additional conditions like Smith-Magenis syndrome and Fragile X syndrome for potential applications of VYKAT XR.

Overall, Soleno Therapeutics demonstrated strong financial performance and strategic growth in 2025, with a focus on expanding its market presence and exploring new therapeutic areas while navigating potential challenges in patient retention and regulatory approval processes.